NCT04634500已完成3 期
Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone
Daewoong Pharmaceutical Co. LTD.1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2020年11月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Change from baseline in HbA1c
研究概览
简要总结
Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Combination with Metformin in Patients With Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control on Metformin Alone.
详细描述
A Multi-center, Randomized, Double-Blind, Active-controlled, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Combination with Metformin in Patients With Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control on Metformin Alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with T2DM aged 19 to 80 years
- •Subjects who have received metformin alone at a fixed dose for the last 8 weeks and has 7% ≤ HbA1c ≤ 10.5%
- •Subjects with BMI of 20-45 kg/m2
- •Subjects who voluntarily decided to participate and provided written consent after being told of the objectives, method, and effects of this study
排除标准
- •Subjects with current or history of hypersensitivity to the IP of this study, metformin or drugs of the same class and their components (e.g., history of hypersensitivity to biguanide or SGLT2 inhibitors)
- •Diabetic ketoacidosis, diabetic coma or precoma within the past year
- •Urinary tract infections or genital infections within
- •Uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg)
- •eGFR < 60 mL/min/1.73 m2
- •Severe heart failure (NYHA class III/IV)
研究组 & 干预措施
Study group
Experimental
DWP16001 A mg, Dapagliflozin placebo
干预措施: Dapagliflozin (Drug)
Control group
Active Comparator
DWP16001 A mg placebo, Dapagliflozin
干预措施: Dapagliflozin (Drug)
结局指标
主要结局
Change from baseline in HbA1c
时间窗: at 24 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on MetforminGlucose Metabolism DisordersMetabolic DiseaseEndocrine System DiseasesDiabetes MellitusDiabetes Mellitus, Type 2NCT05505994Daewoong Pharmaceutical Co. LTD.340
已完成
3 期
The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes MellitusT2DM (Type 2 Diabetes Mellitus)NCT04654390Daewoong Pharmaceutical Co. LTD.270
已完成
1 期
Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)HealthyNCT04064073Daewoong Pharmaceutical Co. LTD.34
Unknown
2 期
Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes MellitusT2DM (Type 2 Diabetes Mellitus)NCT04014023Daewoong Pharmaceutical Co. LTD.196
已完成
3 期
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.T2DM (Type 2 Diabetes Mellitus)NCT04632862Daewoong Pharmaceutical Co. LTD.140